Tibet Duo Rui Pharmaceutical Hits Day Low Amid Price Pressure at CNY 79.18

Tibet Duo Rui Pharmaceutical Co., Ltd. experienced significant volatility on May 25, 2026, with the stock declining by 9.07% and reaching an intraday low of CNY 79.18. This performance stands in contrast to the China Shanghai Composite, which gained 0.96% on the same day. Over the past week, Tibet Duo Rui has seen a decrease of 4.28%, while its monthly performance remains slightly positive at 1.31%. Despite a remarkable annual return of 177.32%, the company has faced ongoing challenges, including a consistent decline in net sales, which have decreased at an annual rate of 15.87% over the last five years. Operating profit has also shown a significant downturn, with a staggering decline of 376.81%. The company has reported negative results for 17 consecutive quarters, raising concerns about its long-term growth prospects. Tibet Duo Rui remains net-debt free, but its return on equity stands at a low average of 9.99%, indicating limited profitability relative to shareholder funds. As a mid-cap player in the pharmaceuticals and biotechnology sector, the company continues to navigate a challenging market landscape.